NEW YORK – Researchers are beginning to uncover biomarkers to help guide treatment for small cell lung cancer, which to date has not benefited from precision oncology advances.
Small cell lung cancer is an aggressive disease that accounts for about 15 percent of all lung cancers. While patients often initially respond to chemotherapy, the disease typically becomes resistant quickly, and the search for biomarkers that might predict treatment response has been hampered by tissue availability.